Can we use calcium antagonist better in antihypertensive therapy? Circadian consideration

Pharmacological Research

Volumn 34, Issue 5-6, 1996, Pages 187-191

  Zhang, Weiguo ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antihypertension; Calcium antagonist; Chronotherapy; Circadian; Sympathetic activity

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CIRCADIAN RHYTHM; DRUG EFFICACY; HEART DISEASE; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SIDE EFFECT; VASODILATATION;

EID: 0030295342     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1996.0087     Document Type: Article

References (48)

1. 1. van Zwieten PA, Pfaffendorf M. Similarities and differences between calcium antagonists: pharmacological aspects. J Hypertens 1993; 11: 3-11.
2. 2+ channel blockers. Atherosclerosis 1991; 88: 109-32.
3. 3. van Zwietan PA. Calcium entry blockers (calcium antagonists). In van Zwietan PA, ed. Handbook of hypertension. Amsterdam: Elsevier. 1984: 331-42.
4. 4. Hansson L. Calcium antagonists: an overview. Am Heart J 1991; 122: 308-11.
5. 5. Luft FC, Haller H. Calcium channel blockers in current medical practice: an update for 1993. Clin Exp Hypertens 1993; 15: 1263-76.
6. 6. Zanchetti A. Introduction. J Hypertens 1993; 11: 1.
7. 7. Leonetti G, Rappelli A. Are there differences in the renal effects of calcium antagonists? J Hypertens 1993; 11: 45-8.
8. 8. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H. Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of international nifedipine trial on antiatherosclerotic therapy (INTACT). Lancet 1990; 335: 1109-13.
9. 9. Hof RP, Tapparelli C, Weinstein DB. Hemodynamic, antivasoconstrictor, and antiatherosclerotic effects of calcium antagonist in animal models of atherosclerosis. J Cardiovasc Pharmacol 1990; 15: 7-12.
10. 10. Waters D, Lesperance J, Francetich M, Causey D, Theroux P, Chiang YK, Hudon G, Lemarbre L, Reitman M, Joyal M, Gosselin G, Dyrda I, Macer J, Havel RJ. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation 1990; 82: 1940-53.
11. 11. Furberg CD. Effect of isradipine and diuretic on early carotid atherosclerosis in hypertension. J Hypertens 1994; 12: 67.
12. 12. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary disease. Part 2, Short-term reduction in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
13. 13. MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of the evidence in 1994. J Vasc Med Biol 1993; 4: 265-71.
14. 14. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Gordwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.
15. 15. The CAPPP Group. The captopril prevention project, a prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. J Hypertens 1990; 8: 985-90.
16. 16. Yusuf S, Lessem J, Jha P, Lonn E. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. J Hypertens 1993; 11: 61-73.
17. 17. Glasser SP, Clark PI, Lipicky RJ, Hubbard JM, Yusuf A. Exposing patients with chronic, stable, exertional angina to placebo periods in drug trials. JAMA 1991; 265: 1550-4.
18. 18. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991; 67: 1295-7.
19. 19. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-31.
20. 20. Pahor M, Guralnik JM, Cortic MC, Foley DJ, Carbonin P, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43: 1191-7.
21. 21. Amery A, Birkenhäger W, Bulpitt CJ, Clement D, De Leeuw P, Dollery CT, Fagard R, Fletcher A, Forette F, Leonetti G, for SYST-EUR. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: objective, protocol, and organization. Ageing 1991; 3: 287-302.
22. 22. Dahlöf B, Hansson L, Lindholm LH, Schersten B, Wester PO, Ekbom T, Hedner T, de Faire U. STOP-Hypertension-2: A prospective intervention trial of 'newer' vs 'older' treatment alternatives in old patients with hypertension. Blood Pressure 1993; 2: 136-41.
23. 23. The NORDIL Study Group. The Nordic Diltiazem Study. An intervention study in hypertension comparing calcium antagonist based treatment with conventional therapy. Blood Pressure 1993; 2: 312-21.
24. 24. Hansson L. Status of current therapy for hypertension. Blood Press 1995; 4: 93-8.
25. 25. The multicenter diltiazem postinfarction trial research group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. New Engl J Med 1988; 319: 385-92.
26. 26. The Danish study group on verapamil in myocardial infarction. Effect of Verapamil on mortality and major events after acute myocardial infarction (The Danish verapamil infarction trial II - DAVIT II). Am J Cardiol 1990; 66: 779-85.
27. 27. Fifer MA, Colucci WS, Lorell B, Jaski BE, Barry WH. Inotropic vascular and neuroendocrine effects of nifedipine in heart failure: comparison with nitroprusside. J Am Coll Cardiol 1985; 5: 731-7.
28. 28. Elkayam U, Roth A, Hsueh W, Weber L, Freidenberger L, Rahimtoola SH. Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure. Am Heart J 1986; 111: 1130-8.
29. 29. Barjon JN, Rouleau JL, Bichet D, Juneau C, De Champlain J. Chronic renal and neurohumoral effects of calcium entry blocker nisodipine in patients with congestive heart failure. J Am Coll Cardiol 1987; 9: 622-30.
30. 30. Packer M. Calcium channel blockers in chronic heart failure. The risks of 'physiologically rational' therapy. Circulation 1990; 82: 2254-7.
31. 31. Leenen FHH, Holliwell DL. Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 1992; 69: 639-45.
32. 32. Ruzicka M, Leenen FHH. Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists. In Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis and management. New York: Raven Press, 1995: 2815-25.
33. 33. Lindqvist M, Kahan T, Melcher A, Hjemdahl P. Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension 1994; 24: 287-96.
34. 34. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79: 733-43.
35. 35. Cooke HM, Lynch A. Biorhythms and chronotherapy in cardiovascular disease. Am J Hosp Pharm 1994; 51: 2569-80.
36. 36. Muller JE, Mangel B. Circadian variation and triggers of cardiovascular disease. Cardiology 1994; 85: 3-10.
37. 37. Willich SN, Linderer T, Wegscheider K, Schroder R. Increased risk of myocardial infarction in the morning. J Am Coll Cardiol 1988; 11: 28.
38. 38. Mulcahy D, Cunningham D, Crean P, Wright C, Keegan J, Quyyumi A, Park A, Fox K. Circadian variation of total ischaemic burden and its alteration with anti-anginal agents. Lancet 1988; 2: 755-9.
39. 39. Menard J. Critical assessment of combination therapy development. Blood Pressure 1993; 2: 5-9.
40. 40. Ruzicka M, Leenen FHH. Relevance of 24 h blood pressure profile and sympathetic activity for outcome on short-versus long-acting 1,4-dihydropyridine. Am J Hypertens 1994; 9: 86-94.
41. 41. Zanchetti A, Chalmers, J, Arakawa K, Gyarfas I, Hamet P, Hansson L, Julius S, MacMahon S, Mancia G, Menard J, Omae T, Reid J, Safar M. IX - 1993 guidelines for management of mild hypertension: memorandum from a WHO/ISH meeting. Clin Exp Hypertens 1993; 15: 1363-95.
42. 42. Luscher TF, Waeber B. Efficacy and safety of various combination therapies based on a calcium antagonist in essential hypertension: results of a placebo-controlled randomized trial. J Cardiovasc Pharmacol 1993; 21: 305-9.
43. 43. Hrushesky WJM. Timing is everything. The Sciences 1994; 34: 32-7.
44. 44. The Joint National Committee. The fifth report of the joint national committee on detection, evaluation and treatment of high blood pressure (JNC V) 1992; 1-53.
45. 45. Lip GYH, Ferner RE. Poisoning with anti-hypertensive drugs: calcium antagonists. J Hum Hypertens 1995; 9: 155-61.
46. 46. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-301.
47. 47. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-6.
48. 48. Kjekshus JK. Comments-beta-blockers: heart rate reduction, a mechanism of benefit. Eur J Pharmacol 1985; 6: 29-30.